Biopharmaceutical manufacturer BioMarin is giving 340B covered entities refunds for overcharges on five of its six approved medicines from Q1 2019 through Q4 2020.

BioMarin Paying Refunds for Two Years of 340B Overcharges on Pricey Drugs

In Pharma IndustryAugust 24, 2021183 Views

Tom Mirga

Biopharmaceutical manufacturer BioMarin is giving 340B covered entities refunds for overcharges on five of its six approved medicines from Q1 2019 through Q4 2020.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Tom Mirga

Exact matches only

Search in title

Search in content

Search in excerpt

Hidden

*Sign up for news summaries and alerts from 340B Report